作为抗癌剂的微管相互作用天然产物。
Tubulin-interactive natural products as anticancer agents.
机构信息
Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0212, USA.
出版信息
J Nat Prod. 2009 Mar 27;72(3):507-15. doi: 10.1021/np800568j.
Abstract
This review provides an overview of the discovery, structures, and biological activities of anticancer natural products that act by inhibiting or promoting the assembly of tubulin to microtubules. The emphasis is on providing recent information on those compounds in clinical use or in advanced clinical trials. The vinca alkaloids, the combretastatins, NPI-2358, the halichondrin B analogue eribulin, dolastatin 10, noscapine, hemiasterlin, and rhizoxin are discussed as tubulin polymerization inhibitors, while the taxanes and the epothilones are the major classes of tubulin polymerization promoters presented, with brief treatments of discodermolide, eleutherobin, and laulimalide. The challenges and future directions of tubulin-interactive natural products-based drug discovery programs are also discussed briefly.
摘要
这篇综述概述了通过抑制或促进微管蛋白组装来发挥作用的抗癌天然产物的发现、结构和生物活性。重点是提供那些在临床使用或在临床试验中处于先进阶段的化合物的最新信息。长春碱类生物碱、考布他汀类、NPI-2358、海兔内酯类似物埃博霉素、多紫杉醇 10、石蒜碱、海兔内酯和瑞香毒素被讨论为微管蛋白聚合抑制剂，而紫杉醇类和埃坡霉素类则是主要的微管蛋白聚合促进剂类别，简要讨论了 discodermolide、eleutherobin 和 laulimalide。还简要讨论了基于微管蛋白相互作用的天然产物药物发现计划的挑战和未来方向。
相似文献
1
Tubulin-interactive natural products as anticancer agents.作为抗癌剂的微管相互作用天然产物。
J Nat Prod. 2009 Mar 27;72(3):507-15. doi: 10.1021/np800568j.
2
Natural products as antimitotic agents.作为抗有丝分裂剂的天然产物。
Curr Top Med Chem. 2014;14(20):2272-85. doi: 10.2174/1568026614666141130095311.
3
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.在长春花碱结构域与微管蛋白相互作用的天然产物：美登素、根霉素、腐草霉素A、多拉司他汀10和15以及海兔毒素B。
Pharmacol Ther. 1992;55(1):31-51. doi: 10.1016/0163-7258(92)90028-x.
4
Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.Gatorbulin-1 是一种独特的环二肽类化学型，靶向第七个微管蛋白药理学位点。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2021847118.
5
Antimicrotubular drugs binding to vinca domain of tubulin.抗微管药物与微管蛋白的长春花结构域结合。
Mol Cell Biochem. 2003 Nov;253(1-2):41-7. doi: 10.1023/a:1026045100219.
6
Mechanism of action of antitumor drugs that interact with microtubules and tubulin.与微管和微管蛋白相互作用的抗肿瘤药物的作用机制。
Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17. doi: 10.2174/1568011023354290.
7
Towards modern anticancer agents that interact with tubulin.朝着与微管蛋白相互作用的现代抗癌药物发展。
Eur J Pharm Sci. 2019 Apr 1;131:58-68. doi: 10.1016/j.ejps.2019.01.028. Epub 2019 Jan 25.
8
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.海兔毒素B和高海兔毒素B，这两种海洋天然产物可与微管蛋白的长春花结构域结合。通过分析差异细胞毒性数据发现基于微管蛋白的作用机制。
J Biol Chem. 1991 Aug 25;266(24):15882-9.
9
Anticancer therapy with novel tubulin-interacting drugs.使用新型微管蛋白相互作用药物的抗癌治疗。
Drug Resist Updat. 2001 Dec;4(6):392-401. doi: 10.1054/drup.2002.0230.
引用本文的文献
1
Discovery of nostatin A, an azole-containing proteusin with prominent cytostatic and pro-apoptotic activity.诺他汀A的发现，一种含唑类的变形菌素，具有显著的细胞抑制和促凋亡活性。
Org Biomol Chem. 2025 Jan 2;23(2):449-460. doi: 10.1039/d4ob01395f.
2
Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.用于癌症治疗的草药疗法：植物治疗功效综述
Biologics. 2024 Sep 10;18:229-255. doi: 10.2147/BTT.S484068. eCollection 2024.
3
Natural Anticancer Peptides from Marine Animal Species: Evidence from In Vitro Cell Model Systems.来自海洋动物物种的天然抗癌肽：体外细胞模型系统的证据
Cancers (Basel). 2023 Dec 20;16(1):36. doi: 10.3390/cancers16010036.
4
Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics.通过工程纳米材料扰乱细胞骨架以增强癌症治疗效果。
Bioact Mater. 2023 Jun 29;29:50-71. doi: 10.1016/j.bioactmat.2023.06.016. eCollection 2023 Nov.
5
Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.微管稳定剂与前列腺癌之间的相互作用
Cancers (Basel). 2023 Jun 23;15(13):3308. doi: 10.3390/cancers15133308.
6
Effect of the Marine Polyketide Plocabulin on Tumor Progression.海洋聚酮化合物 Plocabulin 对肿瘤进展的影响。
Mar Drugs. 2022 Dec 31;21(1):38. doi: 10.3390/md21010038.
7
Integrated analysis reveals effects of bioactive ingredients from (Girard) Kuntze on hypoxia-inducible factor (HIF) activation.综合分析揭示了来自（吉拉德）孔茨的生物活性成分对缺氧诱导因子（HIF）激活的影响。
Front Plant Sci. 2022 Oct 27;13:994036. doi: 10.3389/fpls.2022.994036. eCollection 2022.
8
Synthesis and antitumor activity of litseaone B analogues as tubulin polymerisation inhibitors.作为微管聚合抑制剂的乌药烷 B 类似物的合成及抗肿瘤活性。
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2530-2539. doi: 10.1080/14756366.2022.2122962.
9
Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides.改变社会的药物：属于紫杉烷类、大环内酯类和非核糖体肽的微管靶向药物。
Molecules. 2022 Sep 1;27(17):5648. doi: 10.3390/molecules27175648.
10
Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin.苯并吡喃酮类似物的细胞毒性及紫檀芪和苯并吡喃酮的代谢途径。
Bioorg Chem. 2022 Aug;125:105915. doi: 10.1016/j.bioorg.2022.105915. Epub 2022 May 27.
本文引用的文献
1
(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.（+）-软海绵素：全合成、新型类似物的构建及生物学评价。
Tetrahedron. 2007 Jan 7;64(2):261-298. doi: 10.1016/j.tet.2007.10.039.
2
Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.沙戈匹隆（ZK-EPO）：从天然产物到全合成临床开发候选药物。
Expert Opin Investig Drugs. 2008 Nov;17(11):1735-48. doi: 10.1517/13543784.17.11.1735.
3
Clinical status of anti-cancer agents derived from marine sources.海洋来源抗癌药物的临床状况
Anticancer Agents Med Chem. 2008 Aug;8(6):603-17.
4
Natural products to drugs: natural product-derived compounds in clinical trials.从天然产物到药物：临床试验中的天然产物衍生化合物
Nat Prod Rep. 2008 Jun;25(3):475-516. doi: 10.1039/b514294f. Epub 2008 May 7.
5
Protein nanoparticles as drug carriers in clinical medicine.蛋白质纳米颗粒作为临床医学中的药物载体。
Adv Drug Deliv Rev. 2008 May 22;60(8):876-85. doi: 10.1016/j.addr.2007.08.044. Epub 2008 Feb 7.
6
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.新型紫杉烷类药物拉罗他赛（XRP9881）用于既往接受过紫杉烷类治疗的转移性乳腺癌患者的II期多中心研究。
Ann Oncol. 2008 Jul;19(7):1255-1260. doi: 10.1093/annonc/mdn060. Epub 2008 Apr 1.
7
Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.埃坡霉素及紫杉烷耐药疾病中微管调节剂的新类似物。
Expert Opin Investig Drugs. 2008 Apr;17(4):523-46. doi: 10.1517/13543784.17.4.523.
8
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model.那可丁在人非小细胞肺癌异种移植模型中的抗肿瘤活性。
Cancer Chemother Pharmacol. 2008 Dec;63(1):117-26. doi: 10.1007/s00280-008-0720-z. Epub 2008 Mar 13.
9
The structure activity relationship of discodermolide analogues.Discodermolide类似物的构效关系。
Mini Rev Med Chem. 2008 Mar;8(3):276-84. doi: 10.2174/138955708783744137.
10
New taxanes in development.正在研发的新型紫杉烷类药物。
Expert Opin Investig Drugs. 2008 Mar;17(3):335-47. doi: 10.1517/13543784.17.3.335.
Zotero 插件